A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)

Inclusion Criteria:

* One or more of the following symptoms: abnormal menstrual bleeding, infertility related to fibroids, pelvic pain, and/or bulk/pressure related symptoms attributed to fibroids: i.e., pelvic pressure, abdominal enlargement, abdominal bloating, gastrointestinal pressure symptoms (backache, constipation), dysfunction of the urinary bladder (urinary frequency, urinary retention), vaginal pressure, and rectal pressure.
* Severity of the symptom(s) warrants invasive treatment
* Willing and able to complete the follow-up requirements outlined in the study design section of the protocol
* Willing to sign a consent form

Exclusion Criteria:

* Active pelvic inflammatory disease or infection
* Any malignancy of the pelvic region
* Endometrial neoplasia or hyperplasia
* Presence of one or more submucosal fibroid(s) with more than 50% growth into the uterine cavity
* Presence of pedunculated serosal fibroid as the dominant fibroid(s)
* Fibroids with significant collateral feeding by vessels other than the uterine arteries
* Presence of arteries supplying the fibroid are not large enough to accept 700-900 micron or 900-1200 micron microspheres
* Coagulopathy
* Atypical anatomy that will not allow for bilateral UFE
* Subject with known severe contrast allergy
* Subjects with known moderate to severe renal disease